On 14 December 2005, orphan designation (EU/3/05/333) was granted by the European Commission to DKA Consult ApS, Denmark, for eptacog alpha (activated) for the treatment of diffuse alveolar haemorrhage.
The sponsorship was transferred to Pharmaorigin ApS, Denmark, in May 2007. The sponsorship was transferred to Savara ApS, Denmark in September 2016. The sponsor’s address was updated in November 2019.
eptacog alfa (activated)
|Disease / condition||
Treatment of diffuse alveolar haemorrhage
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;